Generic name:gemtuzumab (intravenous route) [ jem-TOOZ-oo-mab-oh-zoe-ga-MYE-sin ]
Drug class:CD33 monoclonal antibodies
Medically reviewed by Drugs.com. Last updated on May 16, 2022.
Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of gemtuzumab ozogamicin as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with gemtuzumab ozogamicin
Commonly used brand name(s)
In the U.S.
- Mylotarg
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Antibody Drug Conjugate
Uses for Mylotarg
Gemtuzumab injection is used alone or together with other medicines (eg, cytarabine, daunorubicin) to treat newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults. It is also used alone to treat CD33-positive AML that has come back (relapsed) or after other medicines did not work well (refractory).
Gemtuzumab is an antineoplastic (cancer) medicine. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal cells may also be affected by gemtuzumab, other side effects can occur. Before you begin treatment, talk to your doctor about the benefits of this medicine as well as the possible risks of using it.
This medicine is to be given only by or under the direct supervision of your doctor.
Before using Mylotarg
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any ot..
